MMP2 and prostate cancer: LYC inhibits EGF-induced JAK/STAT signaling as well as various downstream STAT3 targets, such as cyclin D1, Bcl-2, Bcl-xL, matrix metalloproteinase 2 (MMP2), and the EMT promoter Twist, which lowers prostate cancer cell line proliferation, migration, invasion (Hu et al., 2015).